
XAIR Stock Forecast & Price Target
XAIR Analyst Ratings
Bulls say
Beyond Air is a biopharmaceutical company that is poised for success with its innovative NO Generator and Delivery System, strategic commercial leadership, and encouraging clinical data in both pulmonary hypertension and cancer indications. With a strong sales and operating focus, the company is well-positioned to drive utilization and establish key partnerships domestically and internationally, making it a promising investment choice. Key metrics such as increasing commercial revenue and strong clinical trial results contribute to a positive outlook for Beyond Air's stock.
Bears say
Beyond Air is facing several significant risks, including financial and capital risks due to their heavy reliance on external funding, commercialization risks due to the competitive market for respiratory treatments, and clinical development risks as their treatments are still in the early stages of testing. Additionally, the company faces several third-party dependency risks, as their success is tied to partnerships and collaborations. There are also intellectual property risks, as securing patents and protecting their technology may be costly. Operational risks, such as manufacturing and distribution challenges, could also impact the company's performance. Finally, there are stockholder and employee risks, as a negative outlook may lead to decreased investor confidence and talent retention.
This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.
XAIR Analyst Forecast & Price Prediction
Start investing in XAIR
Order type
Buy in
Order amount
Est. shares
0 shares